Home › Alzheimer's Disease › Texas › El Paso
Alzheimer's Disease clinical trials in El Paso, TX
4 studies for Alzheimer's Disease are looking for participants at sites in and around El Paso (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RecruitingPhase 3
- Local Institution - 1643, El Paso
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
RecruitingPhase 3
- Advanced Neuro Research Center - El Paso, El Paso
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
RecruitingPhase 3
- Advanced Neurology Epilepsy and Sleep Center, El Paso
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RecruitingPhase 2
- ANESC Research, El Paso
About Alzheimer's Disease
Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills. It's the most common cause of dementia among older adults.
More about Alzheimer's Disease on MedlinePlus
Alzheimer's Disease trials in other cities
- Boston, MA26 studies
- Orlando, FL25 studies
- St. Louis, MO22 studies
- New York City, NY21 studies
- Miami, FL20 studies
- Tampa, FL17 studies
- Atlanta, GA16 studies
- Philadelphia, PA15 studies
- Phoenix, AZ15 studies
- The Villages, FL15 studies
- Los Angeles, CA14 studies
- Indianapolis, IN14 studies
Other studies in El Paso
- Obesity10 studies
- Overweight8 studies
- Heart Failure7 studies
- Non-Small Cell Lung Cancer6 studies
- Breast Cancer6 studies
- COPD5 studies
- Metastatic Cancer5 studies
- Burkitt Lymphoma4 studies
- Lung Cancer4 studies
- Asthma4 studies
- Cancer (all types)4 studies
- Idiopathic Pulmonary Fibrosis4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.